Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

Journal of Experimental Medicine

Volumn 203, Issue 2, 2006, Pages 413-424

  Querec, Troy ^a   Bennouna, Soumaya ^a   Alkan, Sefik ^c   Laouar, Yasmina ^d   Gorden, Keith ^c   Flavell, Richard ^d   Akira, Shizuo ^e   Ahmed, Rafi ^a   Pulendran, Bali ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c 3M COMPANY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 12P40; INTERLEUKIN 6; LIVE VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; YELLOW FEVER VACCINE; YF 17 D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL STRAIN HEK293; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECEPTOR UPREGULATION; TH1 CELL; TH2 CELL; VACCINATION; VIRUS IMMUNITY; YELLOW FEVER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNITY, ACTIVE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, INTERLEUKIN-1; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; VACCINES, ATTENUATED; YELLOW FEVER VACCINE;

EID: 32944455665     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20051720     Document Type: Article

References (79)

1. Theiler, M., and H.H. Smith. 1937. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:787-800.
2. Theiler, M., and H.H. Smith. 1937. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J. Exp. Med. 65:767-786.
3. Niedrig, M., M. Lademann, P. Emmerich, and M. Lafrenz. 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health. 4:867-871.
4. Poland, J.D., C.H. Calisher, T.P. Monath, W.G. Downs, and K. Murphy. 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 59:895-900.
5. Co, M.D., M. Terajima, J. Cruz, F.A. Ennis, and A.L. Rothman. 2002. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology. 293:151-163.
6. Arroyo, J., C. Miller, J. Catalan, G.A. Myers, M.S. Ratterree, D.W. Trent, and T.P. Monath. 2004. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78:12497-12507.
7. Bhatt, T.R., M.B. Crabtree, F. Guirakhoo, T.P. Monath, and B.R. Miller. 2000. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg. 62:480-484.
8. Guirakhoo, F., Z.X. Zhang, T.J. Chambers, S. Delagrave, J. Arroyo, A.D. Barrett, and T.P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 257:363-372.
9. Guirakhoo, F., J. Arroyo, K.V. Pugachev, C. Miller, Z.X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T.P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
10. Pugachev, K.V., F. Guirakhoo, F. Mitchell, S.W. Ocran, M. Parsons, B.W. Johnson, O.L. Kosoy, R.S. Lanciotti, J.T. Roehrig, D.W. Trent, and T.P. Monath. 2004. Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am. J. Trop. Med. Hyg. 71:639-645.
11. Guirakhoo, F., K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, et al. 2004. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78:4761-4775.
12. Molenkamp, R., E.A. Kooi, M.A. Lucassen, S. Greve, J.C. Thijssen, W.J. Spaan, and P.J. Bredenbeek. 2003. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J. Virol. 77:1644-1648.
13. Monath, T.P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C. Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, C. Johnson, and P. Bedford. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188:1213-1230.
14. Tao, D., G. Barba-Spaeth, U. Rai, V. Nussenzweig, C.M. Rice, and R.S. Nussenzweig. 2005. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J. Exp. Med. 201:201-209.
15. McAllister, A., A.E. Arbetman, S. Mandl, C. Pena-Rossi, and R. Andino. 2000. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J. Virol. 74:9197-9205.
16. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 430:257-263.
17. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995.
18. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-376.
19. Kawai, T., and S. Akira. 2005. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17:338-344.
20. Germain, R.N. 2004. An innately interesting decade of research in immunology. Nat. Med. 10:1307-1320.
21. Shortman, K., and Y.J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151-161.
22. Pulendran, B. 2005. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174:2457-2465.
23. Poltorak, A., X. He, I. Smirnova, M.Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:2085-2088.
24. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 11:443-451.
25. Werts, C., R.I. Tapping, J.C. Mathison, T.H. Chuang, V. Kravchenko, I. Saint Girons, D.A. Haake, P.J. Godowski, F. Hayashi, A. Ozinsky, et al. 2001. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat. Immunol. 2:346-352.
26. Hirschfeld, M., J.J. Weis, V. Toshchakov, C.A. Salkowski, M.J. Cody, D.C. Ward, N. Qureshi, S.M. Michalek, and S.N. Vogel. 2001. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 69:1477-1482.
27. Hiramine, H., K. Watanabe, N. Hamada, and T. Umemoto. 2003. Porphyromonas gingivalis 67-kDa fimbriae induced cytokine production and osteoclast differentiation utilizing TLR 2. FEMS Microbiol. Lett. 229:49-55.
28. Underhill, D.M., A. Ozinsky, A.M. Hajjar, A. Stevens, C.B. Wilson, M. Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 401:811-815.
29. Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
30. Krug, A., A.R. French, W. Barchet, J.A. Fischer, A. Dzionek, J.T. Pingel, M.M. Orihuela, S. Akira, W.M. Yokoyama, and M. Colonna. 2004. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity. 21:107-119.
31. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Tolllike receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198:513-520.
32. Takeshita, F., C.A. Leifer, I. Gursel, K.J. Ishii, S. Takeshita, M. Gursel, and D.M. Klinman. 2001. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167:3555-3558.
33. Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 303:1529-1531.
34. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 303:1526-1529.
35. Lund, J.M., L. Alexopoulou, A. Sato, M. Karow, N.C. Adams, N.W. Gale, A. Iwasaki, and R.A. Flavell. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA. 101:5598-5603.
36. Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 413:732-738.
37. Guillot, L., R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard, and M. Si-Tahar. 2005. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J. Biol. Chem. 280:5571-5580.
38. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. Shamel, S. Sovath, J. Goode, et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA. 101:3516-3521.
39. Gorden, K.B., K.S. Gorski, S.J. Gibson, R.M. Kedl, W.C. Kieper, X. Qiu, M.A. Tomai, S.S. Alkan, and J.P. Vasilakos. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR 8. J. Immunol. 174:1259-1268.
40. Ito, T., Y.H. Wang, and Y.J. Liu. 2005. Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR 9. Springer Semin. Immunopathol. 26:221-229.
41. Coccia, E.M., M. Severa, E. Giacomini, D. Monneron, M.E. Remoli, I. Julkunen, M. Cella, R. Lande, and G. Uze. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34:796-805.
42. Heit, A., T. Maurer, H. Hochrein, S. Bauer, K.M. Huster, D.H. Busch, and H. Wagner. 2003. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J. Immunol. 170:2802-2805.
43. Datta, S.K., V. Redecke, K.R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S.P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170:4102-4110.
44. Pulendran, B., P. Kumar, C.W. Cutler, M. Mohamadzadeh, T. Van Dyke, and J. Banchereau. 2001. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 167:5067-5076.
45. Dillon, S., A. Agrawal, T. Van Dyke, G. Landreth, L. McCauley, A. Koh, C. Maliszewski, S. Akira, and B. Pulendran. 2004. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 172:4733-4743.
46. Netea, M.G., R. Sutmuller, C. Hermann, C.A. Van der Graaf, J.W. Van der Meer, J.H. van Krieken, T. Hartung, G. Adema, and B.J. Kullberg. 2004. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J. Immunol. 172:3712-3718.
47. Sing, A., D. Rost, N. Tvardovskaia, A. Roggenkamp, A. Wiedemann, C.J. Kirschning, M. Aepfelbacher, and J. Heesemann. 2002. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J. Exp. Med. 196:1017-1024.
48. Agrawal, S., A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, T. Van Dyke, and B. Pulendran. 2003. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171:4984-4989.
49. Redecke, V., H. Hacker, S.K. Datta, A. Fermin, P.M. Pitha, D.H. Broide, and E. Raz. 2004. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. 172:2739-2743.
50. Barba-Spaeth, G., R.S. Longman, M.L. Albert, and C.M. Rice. 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 202:1179-1184.
51. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301:640-643.
52. Hoebe, K., X. Du, P. Georgel, E. Janssen, K. Tabeta, S.O. Kim, J. Goode, P. Lin, N. Mann, S. Mudd, et al. 2003. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature. 424:743-748.
53. Horng, T., G.M. Barton, and R. Medzhitov. 2001. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol. 2:835-841.
54. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and S. Akira. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169:6668-6672.
55. Fitzgerald, K.A., D.C. Rowe, B.J. Barnes, D.R. Caffrey, A. Visintin, E. Latz, B. Monks, P.M. Pitha, and D.T. Golenbock. 2003. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J. Exp. Med. 198:1043-1055.
56. Yamamoto, M., S. Sato, H. Hemmi, H. Sanjo, S. Uematsu, T. Kaisho, K. Hoshino, O. Takeuchi, M. Kobayashi, T. Fujita, K. Takeda, and S. Akira. 2002. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR 4. Nature. 420:324-329.
57. Oshiumi, H., M. Matsumoto, K. Funami, T. Akazawa, and T. Seya. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat. Immunol. 4:161-167.
58. Bieback, K., E. Lien, I.M. Klagge, E. Avota, J. Schneider-Schaulies, W.P. Duprex, H. Wagner, C.J. Kirschning, V. Ter Meulen, and S. Schneider-Schaulies. 2002. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol. 76:8729-8736.
59. Duesberg, U., A. von dem Bussche, C. Kirschning, K. Miyake, T. Sauerbruch, and U. Spengler. 2002. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by toll like receptors (TLRs) 2 and 4. Immunol. Lett. 84:89-95.
60. Dolganiuc, A., S. Oak, K. Kodys, D.T. Golenbock, R.W. Finberg, E. Kurt-Jones, and G. Szabo. 2004. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 127:1513-1524.
61. Zhou, S., E.A. Kurt-Jones, L. Mandell, A. Cerny, M. Chan, D.T. Golenbock, and R.W. Finberg. 2005. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 35:822-830.
62. Kato, H., S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. Matsui, T. Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, and S. Akira. 2005. Cell Type-Specific Involvement of RIG-I in Antiviral Response. Immunity. 23:19-28.
63. Coban, C., K.J. Ishii, T. Kawai, H. Hemmi, S. Sato, S. Uematsu, M. Yamamoto, O. Takeuchi, S. Itagaki, N. Kumar, T. Horii, and S. Akira. 2005. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201:19-25.
64. Triantafilou, K., E. Vakakis, G. Orthopoulos, M.A. Ahmed, C. Schumann, P.M. Lepper, and M. Triantafilou. 2005. TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1. Eur. J. Immunol. 35:2416-2423.
65. Triantafilou, K., G. Orthopoulos, E. Vakakis, M.A. Ahmed, D.T. Golenbock, P.M. Lepper, and M. Triantafilou. 2005. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell. Microbiol. 7:1117-1126.
66. Schnare, M., G.M. Barton, A.C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:947-950.
67. Brightbill, H.D., D.H. Libraty, S.R. Krutzik, R.B. Yang, J.T. Belisle, J.R. Bleharski, M. Maitland, M.V. Norgard, S.E. Plevy, S.T. Smale, et al. 1999. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 285:732-736.
68. Re, F., and J.L. Strominger. 2001. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276:37692-37699.
69. Re, F., and J.L. Strominger. 2004. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J. Immunol. 173:7548-7555.
70. Schaub, B., A. Bellou, F.K. Gibbons, G. Velasco, M. Campo, H. He, Y. Liang, M.W. Gillman, D. Gold, S.T. Weiss, D.L. Perkins, and P.W. Finn. 2004. TLR2 and TLR4 stimulation differentially induce cytokine secretion in human neonatal, adult, and murine mononuclear cells. J. Interferon Cytokine Res. 24:543-552.
71. Ropert, C., and R.T. Gazzinelli. 2004. Regulatory role of Toll-like receptor 2 during infection with Trypanosoma cruzi. J. Endotoxin Res. 10:425-430.
72. van der Most, R.G., L.E. Harrington, V. Giuggio, P.L. Mahar, and R. Ahmed. 2002. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology. 296:117-124.
73. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6:769-776.
74. Roelofs, M.F., L.A. Joosten, S. Abdollahi-Roodsaz, A.W. Van Lieshout, T. Sprong, F.H. van den Hoogen, W.B. Van Den Berg, and T.R. Radstake. 2005. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52:2313-2322.
75. Wille-Reece, U., B.J. Flynn, K. Lore, R.A. Koup, R.M. Kedl, J.J. Mattapallil, W.R. Weiss, M. Roederer, and R.A. Seder. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA. 102:15190-15194.
76. Janeway, C.A., Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54:1-13.
77. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
78. Hussain, A.I., J.A. Johnson, M. Da Silva Freire, and W. Heneine. 2003. Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J. Virol. 77:1105-1111.
79. Pulendran, B. 2004. Immune activation: death, danger and dendritic cells. Curr. Biol. 14:R30-R32.